Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 4 | 1 |
Section 1 - About the Company | 4 | 1 |
Sprint Bioscience AB - Key Facts | 5 | 1 |
Sprint Bioscience AB - Key Employees | 6 | 1 |
Sprint Bioscience AB - Major Products and Services | 7 | 1 |
Sprint Bioscience AB - Pharmaceutical Pipeline Products Data | 8 | 3 |
Sprint Bioscience AB, Pipeline Products by Therapy Area | 8 | 1 |
Sprint Bioscience AB, Pipeline Products by Development Phase | 9 | 2 |
Sprint Bioscience AB - History | 11 | 1 |
Sprint Bioscience AB - Locations And Subsidiaries | 12 | 1 |
Head Office | 12 | 1 |
Section 2 Company Analysis | 13 | 1 |
Company Overview | 13 | 1 |
Sprint Bioscience AB - Key Competitors | 14 | 1 |
Section 3 Company Financial Ratios | 15 | 1 |
Financial Ratios - Capital Market Ratios | 15 | 1 |
Financial Ratios - Annual Ratios | 16 | 2 |
Performance Chart | 18 | 1 |
Financial Performance | 18 | 1 |
Financial Ratios - Interim Ratios | 19 | 1 |
Financial Ratios - Ratio Charts | 20 | 1 |
Section 4 Company s Lifesciences Financial Deals and Alliances | 21 | 2 |
Sprint Bioscience AB, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016 | 21 | 1 |
Sprint Bioscience AB, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016 | 22 | 1 |
Sprint Bioscience AB, Recent Deals Summary | 23 | 1 |
Section 5 Company s Recent Developments | 24 | 1 |
Jul 01, 2016: Grant for a new form of treatment of type 2 diabetes | 24 | 1 |
Section 6 Appendix | 25 | 5 |
Methodology | 25 | 1 |
Ratio Definitions | 25 | 4 |
About GlobalData | 29 | 1 |
Contact Us | 29 | 1 |
Disclaimer | 29 | 1 |